Practice Signal
Updated October 2026 with LIBREXIA ACS: milvexian failed after acute coronary syndrome, narrowing the class to secondary stroke prevention while asundexian's FDA decision approaches.
Factor XI/XIa inhibitors are moving from clinical trials to regulatory review, with asundexian now the first molecule in this class under FDA priority review for US market approval. OCEANIC-STROKE demonstrated a 26% reduction in recurrent ischemic stroke (HR 0.74, P<0.001) without increased major bleeding when added to antiplatelet therapy in 12,327 patients with noncardioembolic stroke or high-risk TIA. The class includes two oral FXIa inhibitors (asundexian, milvexian) and one subcutaneous anti-FXI monoclonal antibody (abelacimab), each pursuing different indications with different results. Asundexian failed in atrial fibrillation (OCEANIC-AF terminated early, HR 3.79 for stroke vs apixaban), and milvexian added to antiplatelet therapy after acute coronary syndrome did not reduce cardiovascular death, MI or ischemic stroke in LIBREXIA ACS (HR 1.05; 95% CI 0.91-1.21). Milvexian and abelacimab AF trials remain ongoing, but so far the class has one proven home: secondary prevention after noncardioembolic stroke. For acute care pharmacists, the practical question is no longer whether FXIa inhibition works, but how to build formulary frameworks for a drug that looks like an anticoagulant, acts on the coagulation cascade, yet has a bleeding profile indistinguishable from placebo.
Asundexian has crossed from pivotal trial to active regulatory review. Bayer's NDA was accepted under FDA priority review in May 2026, with parallel filings in Japan and China. The 6-month priority review clock points to an FDA action date in late 2026. If approved, asundexian would be the first oral factor XIa inhibitor on the US market and the first new anticoagulant mechanism class since the direct oral Xa inhibitors arrived over a decade ago.
The class-level picture shows three distinct molecules at different stages:
Asundexian (Bayer) is furthest along: positive Phase 3 in secondary stroke prevention, failed Phase 3 in AF, NDA filed.
Milvexian (Bristol Myers Squibb/Janssen) has its first phase 3 readout, and it was negative: LIBREXIA ACS was stopped for futility in November 2025, and the full NEJM report (August 2026) confirmed no reduction in cardiovascular death, MI or ischemic stroke after ACS. LIBREXIA-AF (vs apixaban) and LIBREXIA-STROKE (secondary stroke prevention) are still running.
Abelacimab (Anthos Therapeutics) is the only parenteral option, a subcutaneous anti-FXI monoclonal antibody that showed dramatic bleeding reduction versus rivaroxaban in AZALEA-TIMI 71 (62-69% reduction in major or clinically relevant nonmajor bleeding) and is running LILAC-TIMI 76 in AF.
The mechanism is consistent across the class: factor XI sits at the junction of the contact activation (intrinsic) pathway, which drives pathologic thrombus propagation, and the tissue factor (extrinsic) pathway, which mediates normal hemostatic clot formation. By selectively inhibiting FXIa, these drugs suppress pathologic clotting while largely preserving the hemostatic response. The genetic validation is strong: individuals with congenital factor XI deficiency (hemophilia C) show reduced thrombotic events without clinically significant spontaneous bleeding.
OCEANIC-STROKE showed clear benefit in secondary stroke prevention: ischemic stroke occurred in 6.2% of patients on asundexian versus 8.4% on placebo (HR 0.74, P<0.001), with all secondary endpoints favoring treatment, including a 31% reduction in disabling or fatal stroke (HR 0.69).
OCEANIC-AF, by contrast, was terminated early when asundexian showed a 3.79-fold increase in stroke or systemic embolism versus apixaban, establishing that FXIa inhibition alone cannot replace full anticoagulation for AF. The meta-analysis by Markides et al. (J Thromb Thrombolysis, Oct 2025; PMID 40610712) confirmed this pattern across the class: 61% bleeding reduction but 3.4-fold increased stroke risk in AF settings.
For acute care pharmacy, the operational shift is significant. Asundexian 50 mg once daily was initiated within 72 hours of stroke onset in OCEANIC-STROKE, meaning inpatient pharmacy teams will be the first point of contact. P&T committees should begin evaluating restriction criteria, indication verification processes, and discharge coordination protocols before approval rather than after.
Subscribe to PharmD Signal for the complete evidence synthesis and practice recommendations on every topic, plus every deep analysis we publish.
Become a Subscriber →